12. LAB DIAGNOSIS & CONTROL
Usually clinical
Detecting viral DNA using PCR or
through isolation
Control: notification, isolation and
disinfection
Treatment: Acyclovir
15. MEASLES
Measles is a leading cause of childhood
deaths in developing countries
Annually around 30 million cases of Measles
are seen and about 9 lakh children die
because of Measles
Measles still kills about million people,
annually
16. MEASLES (contd)
Next disease amenable for eradication
Challenges in elimination:
Weak immunization system
High infectious nature
Inaccessible population
Increasing refusal of immunization
Changing epidemiology
Gaps in human and financial resources
17. MEASLES IN INDIA
Major cause of childhood mortality and
morbidity
2% of under 5 mortality in India
Most cases in tribal and remote areas
go unreported
Incidence is steadily declining
20. CHARACTERISTICS OF RASH
Initial symptoms : high fever (103-105属F) & skin rash
Followed by cough, runny nose, and/or conjunctivitis
Rash usually appears about 14 days after exposure
and lasts 5 - 6 days
It begins at the hairline, then involves the face and
upper neck
Over next 3 days, rash gradually proceeds downward
& outward, reaching hands & feet becomes confluent
27. Mumps
More than 85% of children become susceptible
to mumps by the age of 9-12 months and
continue to be so in the first 5 years of life
It is estimated that about 8.5 - 9 lakh cases of
mumps occur in our country every year.
29. Obvious sign of mumps is swelling of parotid
region, because of Acute parotitis.
Swelling usually lasts for 10 days with fever,
Ear-ache, difficulty to talk, eat, open the mouth
for 1-6 days.
Affects various organs like salivary glands -
Parotid glands, kidneys, testicles (Males),
ovaries (females), pancreas, breast and joints
The symptoms- signs of Mumps
30. About 20% people who get mumps develop a painful
swelling of testicles (Orchitis) and 50% will end up with
testicular atrophy. Only 15% of cases of orchitis are
bilateral in which case may leads to infertility.
Mumps can also affect reproductive organs in females
- oophoritis
Sensori-neural (SN) deafness is a chronic
compllication
Mumps can also cause Asceptic Meningitis, joint pain,
pancreatitis, myocarditis and mastitis
Complications of Mumps
34. Rubella - PNAR
Sub-clinical, very mild viral illness, Dx. often missed
Post auricular, sub occipital or cervical adenopathy
Rash mainly face, never confluent, later extends body
Fever may or may not occur, usually low grade, mild
Complications rare arthritis, TCP, Haeg., Encephalt.
Rubella in during pregnancy may lead to miscarriage.
37. The incidence of deformities in
the various stages of pregnancy
3-11 weeks 100% infected fetus
12 weeks 80% infected fetus
13-14 weeks 54% infected fetus
15-16 weeks 35% infected fetus
23-26 weeks 25% infected fetus
Time of maternal infection Result
38. The incidence of deformities in
India
Several studies have clearly shown the link between
congenital defects and Rubella in Indian Children
Study Defect Incidence due to Rubella
Chennai Congenital deafness 29%
Madurai Congenital cataract 26.3%
Delhi Congenital malformations 21%
(12000 samples)
39. The treatment for Rubella
Unfortunately there is no treatment for Rubella.
Vaccination is the only way to prevent all these
complications
In fact, 123 countries i.e. more than 57% of the
countries include Rubella vaccine in their
schedule
Sri Lanka has already included the vaccine in their
EPI program
40. Rubella vaccine should be given to
All girls at puberty (9 years and above)
All women of child bearing age and Hospital workers
After vaccination at least of 3 months of contraception
if missed, Post delivery to protect subsequent pregnancies
42. 1. To ensure adequate protection against Measles
to all children, the WHO, American Academy of
Paediatrics (AAP) and also the Indian Academy
of Paediatrics (IAP) recommend use of two
doses of Measles vaccine.
2. As perthe recommendation of the IAP,
the first dose should be given at 9 months and
the second dose should be given at 16 to 24
months
Recommendations
#6: Herpes zoster occurs in aged individuals when cell mediated immunity declines due to reactivation of latent varicella virus.
Severe in pregnant women, infants and immunocompromised individuals.
#7: Mode of transmission contagious disease and through oropharyngeal secretions, droplet nuclei
Life long immunity
Secondary attack rate 90%
Period of infectivity next slide.
Host: children; life long immunity; pregnancy less than 20 weeks - congenital varicella syndrome;
Environment: winter, spring, coolest, driest months. Heat labile.
#11: Centrifugal in distribution; absent in palms and soles; may involve axilla, buccal mucosa
#14: Age: 12 to 18 months
VZIG: given within 72 hours of exposure; intramuscular route;
#19: Mode of transmission contagious disease and through oropharyngeal secretions, droplet nuclei
Life long immunity
Secondary attack rate 90%
Period of infectivity next slide.
Host: children; life long immunity; malnourished children
Environment: winter, spring, coolest, driest months. Overcrowding
#28: Although the morbidity of mumps is high, the mortality due to this disease is negligible.
#29: Subclinical infections occur. Mode of transmission contagious disease and through oropharyngeal secretions, droplet nuclei
Life long immunity
Secondary attack rate 90%
Period of infectivity next slide.
Host: children; life long immunity; malnourished children; Pregnancy spontaneous abortion in 25% cases
Environment: winter, spring, coolest, driest months. Overcrowding
#34: Subclinical infections occur. Major difference between measles and rubella. Mode of transmission contagious disease and through oropharyngeal secretions, droplet nuclei
Life long immunity
Secondary attack rate is low
Host: children; life long immunity; Pregnancy 40% are susceptible
Environment: winter, spring, coolest, driest months. Overcrowding
#45: Caused by variola virus. Characterized by sudden onset of fever, headache, backache, vomiting and convulsions. Rash 3rd day of fever. By eradicating small pox, we have prevented 2 million deaths per year.
Despite the eradication of small pox, surveillance is still going on. WHO reserves a stock of vaccine sufficient for 200 million people, if an emergency arises.